Should hydralazine be avoided in a patient with hypertrophic obstructive cardiomyopathy, and what alternative medications are recommended?

Hydralazine Should Be Avoided in Hypertrophic Obstructive Cardiomyopathy

Yes, hydralazine is contraindicated in patients with hypertrophic obstructive cardiomyopathy (HOCM) and should be discontinued immediately if currently prescribed. 1

Why Hydralazine is Harmful in HOCM

Hydralazine acts as a pure vasodilator that worsens left ventricular outflow tract (LVOT) obstruction through multiple dangerous mechanisms:

• The "hyperdynamic" circulation caused by hydralazine may accentuate specific cardiovascular inadequacies, creating a particularly hazardous situation in HOCM where dynamic obstruction is already present 2

• Vasodilators reduce afterload and preload, which paradoxically increases the LVOT gradient by allowing the hypertrophied septum to move closer to the mitral valve during systole, worsening obstruction 1

• Myocardial stimulation produced by hydralazine can cause anginal attacks and ECG changes of myocardial ischemia, and the drug has been implicated in myocardial infarction—particularly problematic in HOCM patients who already have compromised coronary perfusion 2

• The 2024 AHA/ACC guidelines explicitly state: "For patients with obstructive HCM, discontinuation of vasodilators (eg, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers) or digoxin may be reasonable because these agents can worsen symptoms caused by dynamic outflow tract obstruction." 1

Recommended Alternative Medications

First-Line Therapy

Nonvasodilating beta-blockers are the recommended first-line treatment and should be titrated to maximally tolerated doses with demonstrated physiologic beta-blockade (resting heart rate suppression): 1

• Metoprolol is preferred among beta-blockers, showing superior gradient reduction (both rest and provoked) and improved symptom scores 3, 4
• Other acceptable nonvasodilating beta-blockers include atenolol, propranolol, and nadolol 1
• Avoid carvedilol and labetalol as their arterial vasodilation properties may accentuate dynamic obstruction 3

Second-Line Therapy (If Beta-Blockers Ineffective or Not Tolerated)

Nondihydropyridine calcium channel blockers should be substituted: 1

• Verapamil is the most effective calcium channel blocker for gradient reduction 4
• Diltiazem is an alternative option 1
• Critical caveat: Verapamil is potentially harmful in patients with severe dyspnea at rest, hypotension, very high resting gradients (>100 mm Hg), or children <6 weeks of age 1

Third-Line/Advanced Therapy (For Persistent Symptoms Despite First-Line Agents)

When symptoms persist despite optimal beta-blocker or calcium channel blocker therapy, escalate to: 1

1. Cardiac myosin inhibitors (adults only):

   • Mavacamten shows the highest efficacy among myosin inhibitors, improving LVOT gradients, symptoms, and functional capacity in 30-60% of patients 1, 4
   • Requires Risk Evaluation and Mitigation Strategy (REMS) monitoring due to potential LVEF reduction <50% in 5.7-10% of patients 1
   • Contraindicated if LVEF <55%; must discontinue if LVEF drops <50% during treatment 3

2. Disopyramide (in combination with AV nodal blocking agent):

   • Shows the highest LVOT gradient reduction among all pharmacological therapies (mean reduction -43.5 mm Hg at rest) 4
   • Must be combined with beta-blocker, verapamil, or diltiazem to prevent rapid ventricular response if atrial fibrillation develops 1, 5
   • Achieved pharmacological symptom control in 64% of patients in a large prospective registry 5

3. Septal reduction therapy (surgical myectomy or alcohol septal ablation) at experienced comprehensive HCM centers 1

Management Algorithm

1. Immediately discontinue hydralazine and all other vasodilators (ACE inhibitors, ARBs, dihydropyridine calcium channel blockers) 1

2. Initiate nonvasodilating beta-blocker (preferably metoprolol), titrating to maximum tolerated dose with evidence of physiologic beta-blockade 1, 3

3. If inadequate response after 4-6 weeks, switch to nondihydropyridine calcium channel blocker (verapamil preferred over diltiazem) 1, 4

4. If symptoms persist despite optimal first-line therapy, add either:

   • Mavacamten (if LVEF ≥55% and adult patient) 1, 3, OR
   • Disopyramide (combined with AV nodal blocker) 1, 5, OR
   • Refer for septal reduction therapy at experienced center 1

Critical Pitfalls to Avoid

• Never use vasodilators including hydralazine, ACE inhibitors, ARBs, or dihydropyridine calcium channel blockers in HOCM 1
• Avoid high-dose diuretics which reduce preload and worsen obstruction; use only low-dose diuretics cautiously if volume overload is present 1
• Do not combine beta-blockers with calcium channel blockers as first-line HCM therapy (unsupported by evidence), though this combination may have a role in managing concomitant hypertension 1
• Never declare beta-blocker failure until physiologic beta-blockade is documented (suppressed resting heart rate) 1